To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

282

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions

Postmenopausal Women With Osteoporosis

Interventions

DRUG

QLG2128

Recommended dosage is 80 μg subcutaneously once daily，52week

DRUG

Teriparatide Injection

Recommended dosage is 20μg subcutaneously once daily，52week

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY